文献速递淋巴瘤

霍奇金淋巴瘤治疗后冠心病与心力衰竭风险预测模型的开发与验证

Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma.
PubMed 文献 · J Clin Oncol · 2022-08-10

该研究基于多中心队列1433例5年霍奇金淋巴瘤生存者开发冠心病与心力衰竭风险预测模型,中位随访24年,341例发生冠心病、102例发生心力衰竭,模型20年和30年预测总体校准度中等至良好、区分度中等(AUC 0.68-0.74),冠心病模型在加拿大708例队列外部验证AUC 0.73-0.74。

要点

  • 基于1433例霍奇金淋巴瘤生存者开发冠心病和心力衰竭风险预测模型。
  • 模型20年和30年预测总体校准度中等至良好,区分度中等(AUC 0.68-0.74)。
  • 冠心病模型外部验证AUC 0.73-0.74,可用于识别需靶向筛查的生存者。

核心结论

  • 研究开发并验证了霍奇金淋巴瘤生存者冠心病和心力衰竭预测模型,总体校准度良好、区分度中等。
  • 模型可用于识别可能从心血管疾病靶向筛查和心血管危险因素早期治疗中获益的霍奇金淋巴瘤生存者。

研究设计与样本

  • 模型开发采用多中心队列,纳入1965年至2000年治疗、诊断时年龄18-50岁的1433例5年霍奇金淋巴瘤生存者。
  • 使用病因别风险模型,在竞争风险(非冠心病和非心力衰竭的其他原因死亡)下估计冠心病和心力衰竭的协变量校正累积发生率。
  • 预测因子包括霍奇金淋巴瘤诊断时年龄、性别、吸烟状态、放疗和蒽环类药物治疗。
  • 冠心病模型外部验证使用加拿大队列708例1988年至2004年治疗、诊断时年龄18-50岁的霍奇金淋巴瘤生存者。

主要发现

  • 中位随访24年,341例生存者发生冠心病,102例发生心力衰竭。
  • 模型可预测治疗后20年和30年冠心病和心力衰竭风险,总体校准度中等至良好、区分度中等(AUC 0.68-0.74)。
  • 冠心病模型外部验证确认区分度中等(AUC 0.73-0.74)。
  • 基于包含处方纵隔放疗剂量的模型,30年冠心病风险范围为4%至78%,心力衰竭风险范围为3%至46%,取决于危险因素。

临床怎么用

  • 作者认为这些模型可用于识别可能从心血管疾病靶向筛查和心血管危险因素早期治疗中获益的霍奇金淋巴瘤生存者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Previous efforts to predict absolute risk of treatment-related cardiovascular diseases (CVDs) have mostly focused on childhood cancer survivors. We aimed to develop prediction models for risk of coronary heart disease (CHD) and heart failure (HF) for survivors of adolescent/adult Hodgkin lymphoma (HL). METHODS: For model development, we used a multicenter cohort including 1,433 5-year HL survivors treated between 1965 and 2000 and age 18-50 years at HL diagnosis, with complete data on administered chemotherapy regimens, radiotherapy volumes and doses, and cardiovascular follow-up. Using cause-specific hazard models, covariate-adjusted cumulative incidences for CHD and HF were estimated in the presence of competing risks of death because of other causes than CHD and HF. Age at HL diagnosis, sex, smoking status, radiotherapy, and anthracycline treatment were included as predictors. External validation for the CHD model was performed using a Canadian cohort of 708 HL survivors treated between 1988 and 2004 and age 18-50 years at HL diagnosis. RESULTS: After a median follow-up of 24 years, 341 survivors had developed CHD and 102 had HF. We were able to predict CHD and HF risk at 20 and 30 years after treatment with moderate to good overall calibration and moderate discrimination (areas under the curve: 0.68-0.74), which was confirmed by external validation for the CHD model (areas under the curve: 0.73-0.74). On the basis of our model including prescribed mediastinal radiation dose, 30-year risks ranged from 4% to 78% for CHD and 3% to 46% for HF, depending on risk factors. CONCLUSION: We developed and validated prediction models for CHD and HF with good overall calibration and moderate discrimination. These models can be used to identify HL survivors who might benefit from targeted screening for CVD and early treatment for CVD risk factors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. de Vries S, Haaksma ML, Jóźwiak K, et al. Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma. J Clin Oncol. 2022. PMID: 35947813. doi:10.1200/JCO.21.02613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。